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ABSTRACT 
Robotic cardiac operations evolved from minimally invasive operations and offer similar theoretical 
benefits, including less pain, shorter length of stay, improved cosmesis, and quicker return to preoperative 
level of functional activity. The additional benefits offered by robotic surgical systems include improved 
dexterity and degrees of freedom, tremor-free movements, ambidexterity, and the avoidance of the fulcrum 
effect that is intrinsic when using long-shaft endoscopic instruments. Also, optics and operative 
visualization are vastly improved compared with direct vision and traditional videoscopes. Robotic systems 
have been utilized successfully to perform complex mitral valve repairs, coronary revascularization, atrial 
fibrillation ablation, intracardiac tumor resections, atrial septal defect closures, and left ventricular lead 
implantation. The history and evolution of these procedures, as well as the present status and future 
directions of robotic cardiac surgery, are presented in this review. 
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INTRODUCTION 
The purported benefits of minimally invasive 
cardiac surgery have been well described; smaller, 
less invasive incisions have the theoretical benefit of 
less pain, shorter length of stay, improved cosmesis, 
and quicker return to preoperative level of func-
tional activity. Minimally invasive approaches have 
become the standard of care at many institutions, 
and excellent results have been achieved. 
As minimally invasive cardiac operations gained 
favor, developments in tele-manipulation tech-
nology and optics fostered the evolution of robotic-
assisted cardiac surgery. Currently, the da Vinci™ 
surgical system (Intuitive Surgical, Sunnyvale, CA, 
USA) is the only US Food and Drug Administration 
(FDA)-approved robotic system used for cardiac 
surgical procedures. Today, robotic heart surgeons 
perform complex mitral valve repairs, coronary 
revascularizations, atrial fibrillation ablations, 
intracardiac tumor resections, and congenital heart 
surgery procedures.  
Before robotic cardiac surgery became a viable 
technique, minimally invasive heart surgery had 
been developed and perfected. These alternatives to 
the gold standard median sternotomy incision 
became increasingly commonplace as advances in 
minimally invasive access and exposure, perfusion 
strategies, and myocardial protection were made. 
The development of these techniques enabled the 
application of endoscopic visualization and instru-
mentation to be developed. This advancing pathway 
led to the robotic tele-manipulation of materials and 
tissues that we have today. The da Vinci™ surgical 
system provides increased operative dexterity for 
surgeons. The wrist-like articulating instruments 
move with six degrees of freedom, compared with 
the four degrees of freedom that endoscopic 
instruments provide. Other benefits are tremor-free 
movements, ambidexterity, and the avoidance of the 
fulcrum effect that is intrinsic when using long-shaft 
endoscopic instruments. Moreover, the system 
improves operative visualization greatly through the 
use of three-dimensional high-definition imaging. 
MITRAL VALVE SURGERY 
The most commonly performed robot-assisted 
cardiac procedure today is a mitral valve repair or 
replacement. As in other less invasive cardiac opera-
tions, minimally invasive and subsequently robotic 
mitral valve surgery evolved from modifications of 
incisions performed previously under direct vision. 
Large series from Cohn and Cosgrove showed that 
mitral surgery, done via minimal access incisions 
and performed under direct vision, offered 
comparable results to the sternotomy approach 
(mortality 1%–3%).1,2 The next step forward was to 
perform mitral surgery using videoscopic assistance. 
The first mitral repair using a videoscope was per-
formed by Carpentier in 1996,3 and the first mitral 
valve replacement was done by Chitwood later the 
same year.4 The Leipzig Heart Center experience 
was reported by Mohr in 1998 and showed excellent 
results in 51 patients who underwent simple mitral 
repair or replacement operations.5 At the same 
meeting, Chitwood reported a 30-day operative 
mortality of 3.2% with no major complications in 31 
patients. This series consisted of a variety of 
complex repairs, including quadrangular resections, 
sliding valvuloplasties, and chordal replacements.6 
The first robotic mitral repair was performed by 
Carpentier in 1998, using an early prototype of the 
da Vinci™ surgical system.7 The following week, 
Mohr repaired five mitral valves and performed a 
coronary revascularization with the device.8 The first 
robotic mitral repair in North America was 
performed by Chitwood in 2000, and consisted of a 
large P2 trapezoidal resection with an intracorporeal 
suture repair followed by annuloplasty band implan-
tation.9 Two subsequent FDA investigational device 
clinical trials led to approval in 2002 of the da 
Vinci™ surgical system for mitral valve surgery in 
the United States.10,11 
Mihaljevic et al. reported their results for 261 
robotic mitral valve repairs done between 2006 and 
2009.12 Their results were compared with mitral 
valve repairs done via complete sternotomy 
(n = 114), partial sternotomy (n = 270), and right 
mini-anterolateral thoracotomy (n = 114). Outcomes 
were compared on an intent-to-treat basis using 
propensity score matching. Median cardiopulmon-
ary bypass time was 42 minutes longer for robotic 
than for complete sternotomy, 39 minutes longer 
than partial sternotomy, and 11 minutes longer than 
right mini-anterolateral thoracotomy (P < 0.0001). 
There were no in-hospital deaths in any group, and 
neurologic, pulmonary, and renal complications 
were similar among groups (P > 0.1). The robotic 
group had the lowest occurrences of atrial 
fibrillation and pleural effusion, contributing to the 
shortest hospital stay (median 4.2 days); 1.0, 1.6, 
and 0.9 days shorter than for complete sternotomy, 
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partial sternotomy, and right mini-anterolateral 
thoracotomy (all P < 0.001), respectively. 
Similar reductions in length of stay were seen at 
the University of Pennsylvania in a comparison of 
39 patients who underwent sternotomy and mitral 
valve repair, or replacement, with 26 patients who 
underwent robotically assisted mitral valve repair or 
replacement.13 Patients who underwent robotic-
assisted surgery experienced shorter mean duration 
of postoperative hospitalization (7.1 versus 10.6 
days; P = 0.04), despite longer cross-clamp and 
bypass times (110 versus 151 minutes, P = 0.0015; 
162 versus 239 minutes, P = 0.001, respectively). 
Mean packed red blood cell transfusion was also 
lower among patients who underwent robotic-
assisted mitral valve surgery (5.0 versus 2.8 units, 
P = 0.04). 
Today, most robot-assisted mitral valve repairs 
are accomplished either through a 3–4-cm right 
anterolateral mini-thoracotomy or a 2-cm lateral 
working port. The articulating EndoWrist™ 
(Intuitive Surgical, Sunnyvale, CA, USA) 
instruments and dynamic left atrial retractor allow 
console surgeons to employ Carpentier’s and others’ 
“toolbox” of repair techniques. 
Our institution has performed over 800 robotic 
mitral valve repairs. Results have been published for 
the first 540 patients.14 Of these, 454 patients 
underwent a lone mitral repair, and 86 had a 
concomitant atrial fibrillation ablation. The average 
cardiopulmonary bypass and cross-clamp times 
were 153 and 116 minutes, respectively, in the lone 
mitral repair patients. The group operative mortality 
was 0.4%. The mean follow-up period was 351 days 
(15–946 days), and 2.9% of patients required a 
reoperation for a failed repair. The cardiopulmonary 
bypass and arrest times have improved with on-
going experience. In the first FDA trial, the average 
cross-clamp time was 150 minutes.10 In the second 
multicenter FDA trial, the average cross-clamp time 
fell to 126 minutes, and there was little variation in 
operative time between centers.11  
We use topographic valve models, derived from 
intra-operative high-quality three-dimensional 
transesophageal echocardiography images to plan a 
successful repair. To isolate the right lung, patients 
are either intubated with a dual-lumen endotracheal 
tube or single-lumen tube with bronchial blocker. 
The patient’s right side then is elevated to 30 
degrees. Cardiopulmonary bypass is achieved via bi-
caval venous cannulation (right internal jugular and 
femoral veins) and femoral arterial cannulation. In 
patients with either inadequate femoral artery size 
or aorto-iliac atherosclerotic disease, the right 
axillary artery is cannulated through an 8-mm poly-
tetrafluoroethylene (PTFE) side-arm graft. The aorta 
is occluded using the Chitwood transthoracic aortic 
cross-clamp (Scanlan International, Minneapolis, 
MN, USA), and antegrade crystalloid Bret-
schneider’s cold cardioplegia is used to arrest the 
heart. In reoperative cases and patients with an 
atherosclerotic or calcified ascending aorta, hypo-
thermic (26°C) fibrillatory arrest is used for myo-
cardial protection. Thereafter, robotic instrument 
arm trocars are inserted into the chest, and the da 
Vinci™ surgical cart is docked by the patient’s left 
side.14 Most commonly we use the following tech-
niques to perform complex mitral repairs: 1) limited 
triangular or quadrangular resection, 2) folding 
valvuloplasty, 3) chordal shortening either by trans-
location or papillary muscle folding, 4) neochord 
implantation, and rarely 5) a leaflet sliding-plasty. 
Formerly we tied all suture knots intracorporeally; 
however, we now use the Cor-Knot™ suture device 
(LSI Solutions, Victor, NY, USA), to secure 
annuloplasty bands. Implementation of this device 
into our routine has significantly reduced our 
cardiopulmonary bypass and cross-clamp times.15 
CORONARY REVASCULARIZATION 
The da Vinci™ surgical system has been used very 
successfully to harvest the internal thoracic artery 
(ITA) for coronary artery bypass grafting (CABG). In 
most cases the ITA-coronary anastomosis has been 
hand-sewn via either a mini-thoracotomy or median 
sternotomy. However, several surgeons have shown 
good results on both beating and arrested hearts 
with totally endoscopic robotic coronary artery 
bypass grafting (TECAB). 
Using a first-generation da Vinci™ surgical 
system, the first TECAB was performed in two 
patients by Loulmet et al. in 1998.16  
Srivastava et al. reported results from 150 
patients who underwent a robotic ITA harvest with 
off-pump CABG via a mini-thoracotomy.17 Later, 
two patients presented with symptomatic graft 
occlusion and were treated successfully by a percu-
taneous intervention, and all grafts were patent in 
55 patients by computed tomographic angiography 
at three months. 
Argenziano reported the FDA multicenter robotic 
coronary bypass Investigational Device Exemption 
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trial in 2006.18 Ninety-eight patients who required a 
single-vessel left anterior descending (LAD) 
revascularization were enrolled at 12 centers. Of 
these, 13 patients were excluded intra-operatively 
for various reasons. Of the 85 remaining patients 
who underwent a TECAB, there were 6% conver-
sions to an open sternotomy, no deaths, no strokes, 
one early re-intervention, and one myocardial 
infarction. Coronary angiography at three months 
revealed greater than a 50% stenosis or an occlusion 
in 7.1% of patients. 
The largest TECAB experience to date was 
published by Bonaros et al.19 Five hundred patients 
from two institutions underwent either a single (n = 
334), double (n = 150), triple (n = 15), or quadruple 
(n = 1) bypass. One-third of the cases had a hybrid 
procedure, i.e. CABG combined with percutaneous 
coronary intervention. The median operative, 
cardiopulmonary bypass, and cross-clamp times 
were 305 minutes, 98 minutes, and 73 minutes, 
respectively. Bilateral internal thoracic arteries were 
used in 22% of patients with a median harvest time 
of 34 minutes for the left and 32 minutes for the 
right. The operative mortality was 1% with 10% 
having conversions to a sternotomy and 5% having 
ITA harvest injuries. Major morbidity and mortality 
was 5% as defined by death, myocardial infarction, 
stroke, vascular complication, or long-term ventila-
tion requiring a tracheostomy. Operative success, as 
defined by freedom from repeat revascularization, 
reoperation for bleeding, or conversion to a larger 
incision, was present in 80% of patients.  
The same group reported on their length of stay 
results for 541 consecutive TECAB patients in two 
different institutions on different continents.20 Their 
overall observed median length of stay (LOS) was 6 
days (range 2–54 days, mean 7.35 days). These data 
are slightly better than LOS data reported by 
Swaminathan and colleagues for CABG patients 
treated during a 17-year period using the 
Nationwide Inpatient Sample (NIS) database, which 
contains information relating to all inpatients of 
non-federal hospitals across the United States.21 In 
this report, median LOS among 8,398,554 CABG 
discharges decreased from 11 to 8 days between 
1988 and 2005 (P < 0.0001). In a more recent co-
hort, the SYNTAX trial, which compared multivessel 
drug-eluting stenting with multivessel CABG in 
patients with triple-vessel or left main coronary 
disease during the 2005 to 2007, reported a post-
operative LOS in the CABG cohort (n = 897) of 9.5 ± 
8 days.22 
The operative approach, as described by Bonaros 
et al., was as follows.19 Suitability for arrested heart 
TECAB was determined by preoperative CT angiog-
raphy. Patients with aortic or peripheral athero-
sclerosis were scheduled for beating heart TECAB. 
The authors preferred an arrested heart approach 
giving better-quality control over performing 
coronary anastomoses. Three robotic arm trocars, 
one camera port and two working ports, were 
introduced into the left (or, if the right coronary 
artery was grafted, into the right) hemithorax under 
single-lung ventilation and carbon dioxide 
insufflation (6 to 10 mmHg). In arrested heart 
TECAB procedures, the femoral or axillary artery 
was cannulated, and an aortic endo-occlusion 
balloon catheter (Endo CPB, Edwards Lifesciences, 
Irvine, CA, or Estech, San Ramon, CA, USA) was 
used to occlude the ascending aorta. The femoral 
vein was also cannulated. In off-pump TECABs, 
peripheral cannulation via the femoral or axillary 
artery and femoral vein were established in order to 
be prepared to institute cardiopulmonary bypass in 
the event of hemodynamic instability, myocardial 
ischemia, or significant space limitations inside the 
chest. The internal thoracic artery was then 
harvested, in a skeletonized fashion, in order to 
optimize graft length. After resection of the 
pericardial fat pad and a pericardiotomy, the 
coronary anastomoses were performed in a hand-
sewn running fashion using 7-0 polypropylene 
suture. In multivessel TECABs, the lateral and back 
walls of the heart were exposed using an endoscopic 
suction stabilizer. An additional 5-mm port in the 
fourth intercostal space left parasternally allowed 
the patient side surgeon to aid in exposure. Intra-
operative assessment by graft angiography or 
Doppler flow measurement was performed. 
To summarize, these reports have shown some 
success with robot-assisted revascularization in 
properly selected patients. However, it is clear that 
TECAB is a challenging procedure, and the learning 
curve is significant. The limited data on this subject 
suggest that robotic coronary operations still have a 
long way to go to uniformly have the same results as 
traditional coronary grafting. Moreover, committed 
and large clinical volume robotic coronary surgeons 
have obtained the best results. The newest genera-
tion of the da Vinci™ SI robotic system with a fourth 
arm and an endostabilizer may enable more 
complex bypass operations to be done on both beat-
ing and arrested hearts. At several centers, and with 
increasing frequency, TECAB is being done in 
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concert with a percutaneous coronary intervention 
as a hybrid operation. This combines the survival 
benefits of left internal thoracic artery (LITA) to 
LAD grafting with the benefits of minimally invasive 
access of the percutaneous coronary intervention 
(PCI). 
ATRIAL FIBRILLATION ABLATION 
The excellent results using the classic Cox maze for 
treating atrial fibrillation operation have been well 
documented.23 Given the known failure rate of 
medical therapy and catheter-based ablation, as well 
as the prevalence of atrial fibrillation in the general 
population (1%–2%) and the elderly (9% in patients 
over 80), the appeal of minimally invasive atrial 
fibrillation surgery is obvious.24 Similar to other 
cardiac operations, the da Vinci™ surgical system 
offers the benefit of improved dexterity and out-
standing visualization, making it an ideal device for 
the precise endocardial placement of probes for 
atrial fibrillation ablation. 
Despite a lack of level I evidence, cryoablation is 
gaining traction among surgeons as a safe and 
effective treatment option for atrial fibrillation. 
Several small retrospective, randomized clinical 
trials have shown a conversion rate to sinus rhythm 
at 12 months in the range of 60%–80%.25  
In 2012, we reported a series of 86 patients who 
underwent combined robotic mitral valve repair 
with concomitant cryomaze.14 Our technique, as 
previously described,26 consists of positioning an 8-
cm flexible argon-cooled flexible probe (Medtronic, 
Minneapolis, MN, USA) to reproduce the Cox maze 
III lesion set. Specialized robotic forceps are used to 
grasp and position the probe. Freedom from atrial 
fibrillation was seen in 83 patients (96.5%) at a 
follow-up period of 351 ± 281 days. Cardiopul-
monary bypass times were longer when cryoablation 
was added to lone mitral valve repair (189 minutes 
versus 153 minutes). Cross-clamp times were also 
longer (131 minutes versus 117 minutes). Although 
longer-term follow-up and level I evidence are 
lacking, we believe that cryoablation is a safe and 
effective technique for the treatment of atrial 
fibrillation. The robotically assisted, right mini-
thoracotomy approach may prove to be an ideal 
minimally invasive surgical treatment for atrial 
fibrillation, whether combined with mitral valve 
surgery or done as a stand-alone operation. 
Robotically assisted epicardial ablation with 
microwave energy has also been performed with few 
complications. The largest series, by Pruitt and 
colleagues, reported on 33 paroxysmal and 17 
permanent atrial fibrillation patients who under-
went thoracoscopic or robotic-assisted off-pump 
epicardial microwave ablation. The investigators 
reported no perioperative death, a mean length of 
stay of 4 days, and a 79.5% success rate overall, with 
a cure rate of 93.5% in paroxysmal disease versus 
69.2% in permanent disease.27 
OTHER CARDIAC PROCEDURES 
Epicardial left ventricular (LV) lead insertion for 
cardiac resynchronization therapy offers an 
important rescue therapy for failed percutaneous 
coronary sinus LV lead placement. Robot-assisted 
LV lead placement is an enticing and safe alternative 
to more invasive epicardial lead surgery in this very-
high-risk population of patients with poor ventricu-
lar function. Often the enlarged ventricle in these 
patients presents a technical challenge, which can be 
safely overcome using robotic assistance. Kamath et 
al. reported 78 consecutive patients, who underwent 
a robot-assisted epicardial lead placement, and 
found improvement in both pacing thresholds and 
lead impedance over both the short (<12 months) 
and long term (>12 months). At 44 ± 21 months’ 
follow-up there were 20 deaths (26%). These 
patients were older (77 ± 7 versus 67 ± 11 years, P = 
0.001) and had a lower ejection fraction (13% ± 7% 
versus 18% ± 9%, P = 0.02) than surviving 
patients.28 In 2006, Derose et al. published their 
midterm results from 42 patients who underwent 
robot-assisted LV replacement. There were no 
mortalities or technical failures.29 
Although much less common than mitral valve 
surgery, coronary revascularization, or atrial fibrilla-
tion ablation, several case reports exist in the litera-
ture for other cardiac procedures, such as intra-
cardiac tumor resections and atrial septal defect 
(ASD) closures. Murphy et al. reported three 
successful atrial myxoma resections using the da 
Vinci™ surgical system in 2005.30 In 2012, Schilling 
et al. reported their results for 17 robot-assisted 
atrial myxoma resections using the da Vinci™ 
surgical system between 2000 and 2009.31 Despite 
no difference in perfusion or cross-clamp times, 
total operative time was shorter in the robot-
assisted group as compared with 29 patients who 
underwent traditional myxoma resection during the 
same time period (2.7 hours versus 3.5 hours, P = 
0.02). There were no mortalities, reoperations for 
bleeding, strokes, or wound infections in either 
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group. There was no significant difference in 
administration of blood products, incidence of 
pneumonia, renal failure, or atrial fibrillation. 
Additionally, there was no difference in length of 
hospital stay or intensive care unit length of stay 
between the robotic-assisted and traditional 
myxoma surgical procedure groups. 
Torracca et al. and Wimmer-Greinecker et al. 
were the first to report small series of patients 
undergoing robotic atrial septal defect (ASD) 
closures.32,33 In a FDA Investigational Device 
Exemption trial, Argenziano et al. demonstrated 
that ASD closure in adults can be performed safely 
and effectively using the da Vinci™ surgical 
system.34 Their median cross-clamp time was 32 
minutes. Bonaros et al. demonstrated no mortalities 
or residual shunts in 17 patients undergoing robot-
assisted ASD closures.35 This study demonstrated a 
steep operative time learning curve. Gao et al. 
reported on 24 patients who underwent robot-
assisted ASD closures with the heart beating; 14 of 
these defects were repaired with an autologous 
pericardial patch, and 10 were closed primarily. 
There were no mortalities or residual ASD by echo-
cardiography.36 As many of these procedures were 
done in young, physically active patients, the 
robotically assisted, totally endoscopic approach of 
ASD closure offers the tangible benefits of decreased 
pain, sternal stability, and improved cosmesis. 
THE FUTURE 
Currently, there are several successful robotic 
cardiac surgery centers. Whether this technology 
will continue to gain more widespread acceptance 
remains to be seen. Despite all of the above-
described benefits, several limitations have 
hampered the acceptance of robotic heart surgery. 
With improved technology, many of these limita-
tions should also diminish. For instance, many 
surgeons remain concerned about the lack of haptic 
feedback. Robotic surgeons have become familiar 
with “ocular tactility,” relying on visual tissue 
deformation to judge the amount of force being 
applied to tissues. In our experience the lack of 
haptic feedback has not been a concern. Future 
robotic systems will likely incorporate strain sensors 
to the instrument arms, allowing for haptic feedback 
and precise control of force. Instrument and camera 
sizes will decrease, and optics will improve, allowing 
for smaller incisions. A greater variety of robotic 
instruments will be developed, allowing for more 
operative options and improved dexterity. Advances 
in three-dimensional echocardiography and model-
ing software will continue to be made, possibly 
allowing a “blueprint” model to be overlaid on the 
operative field image at the console.  
It has become evident that in order to achieve 
success with a robotic cardiac surgery program, 
several key elements are required. For one, the 
concept of a highly specialized and trained robotic 
team is paramount, to include anesthesiologists, 
perfusionists, operating room staff, nurses, and 
surgeons. With limited access to and visualization of 
the heart, skilled echocardiographers are crucial. 
Achieving safe cannulation, planning for complex 
valve repairs, and monitoring cardiac function are 
all predicated on high-quality, three-dimensional 
transesophageal echocardiography. Finally, robotic 
heart surgery centers must have an adequate 
referral base to attain safety and efficiency. To date, 
several centers have achieved success in robotic 
cardiac surgery, performing a variety of heart opera-
tions reproducibly, reliably, effectively, and safely. 
We are confident that this promising technology will 
continue to advance and grow in utilization 
internationally. 
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